{
    "id": 25747,
    "fullName": "FLT3 F691I",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 F691I lies within the protein kinase domain of the Flt3 protein (PMID: 23430109). F691I has been demonstrated to promote secondary drug resistance in the context of FLT3 internal tandem duplication (FLT3-ITD) mutations (PMID: 23392356, PMID: 22409268), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 7054,
                    "pubMedId": 23392356,
                    "title": "The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23392356"
                },
                {
                    "id": 11569,
                    "pubMedId": 22409268,
                    "title": "Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22409268"
                },
                {
                    "id": 3028,
                    "pubMedId": 23430109,
                    "title": "Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23430109"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "F691I",
    "createDate": "11/16/2016",
    "updateDate": "03/16/2020",
    "referenceTranscriptCoordinates": {
        "id": 144490,
        "transcript": "NM_004119",
        "gDna": "chr13:g.28027224A>T",
        "cDna": "c.2071T>A",
        "protein": "p.F691I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9285,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Quizartinib (AC220) in culture (PMID: 23392356).",
            "molecularProfile": {
                "id": 26802,
                "profileName": "FLT3 exon 14 ins FLT3 F691I"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7054,
                    "pubMedId": 23392356,
                    "title": "The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23392356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9278,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).",
            "molecularProfile": {
                "id": 26802,
                "profileName": "FLT3 exon 14 ins FLT3 F691I"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7054,
                    "pubMedId": 23392356,
                    "title": "The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23392356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9276,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing FLT3 ITD and F691I demonstrated reduced response to Sutent (sunitinib) in culture (PMID: 23392356).",
            "molecularProfile": {
                "id": 26802,
                "profileName": "FLT3 exon 14 ins FLT3 F691I"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7054,
                    "pubMedId": 23392356,
                    "title": "The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23392356"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9252,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FLT3 ITD and F691I demonstrated reduced sensitivity to Alunbrig (brigatinib) compared to cells expressing FLT3 ITD in culture (PMID: 27780853).",
            "molecularProfile": {
                "id": 26802,
                "profileName": "FLT3 exon 14 ins FLT3 F691I"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9275,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Rydapt (midostaurin) in culture (PMID: 23392356).",
            "molecularProfile": {
                "id": 26802,
                "profileName": "FLT3 exon 14 ins FLT3 F691I"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7054,
                    "pubMedId": 23392356,
                    "title": "The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23392356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26801,
            "profileName": "FLT3 F691I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26802,
            "profileName": "FLT3 exon 14 ins FLT3 F691I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144491,
            "transcript": "XM_011535015",
            "gDna": "chr13:g.28027167A>T",
            "cDna": "c.2071T>A",
            "protein": "p.F691I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 144490,
            "transcript": "NM_004119",
            "gDna": "chr13:g.28027224A>T",
            "cDna": "c.2071T>A",
            "protein": "p.F691I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}